Swedish biotechnology company Diamyd Medical AB (Nasdaq First North Growth Market:DMYD-B) on Tuesday announced that the South Korean Patent Office has granted a patent for the use of insulin-based antigens to treat autoimmune diabetes in patients with the HLA DR4-DQ8 genetic marker.
This patent, valid until 2035, is the first of its kind globally and reinforces the importance of precision medicine in diabetes care.
Diamyd Medical is currently conducting a Phase 3 trial with its GAD-specific immunotherapy Diamyd in patients with HLA DR3-DQ2, another genetically distinct subgroup of Type 1 diabetes patients.
Up to 90% of Type 1 diabetes patients carry either the HLA DR3-DQ2 or HLA DR4-DQ8 genetic markers.
ANI Pharmaceuticals secures FDA approval for ILUVIEN label expansion
Sterotherapeutics launches Phase 2 clinical trial of ST-002 for Cushing's Syndrome
FDA accepts Alvotech and Teva's application for Eylea biosimilar
Owens & Minor launches ByramConnect digital health platform for diabetes management
NLS Pharmaceutics and Kadimastem plan multi-target approach to diabetes
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Bain Capital to acquire Mitsubishi Tanabe Pharma in USD3.3bn deal
Teladoc Health to acquire Catapult Health to enhance integrated care offerings
NLS Pharmaceutics and Kadimastem announce shareholder approval for merger